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Abstract 
Introduction 
Patients with distributive shock who require high dose vasopressors have a high mortality. 
Angiotensin II (ATII) may prove useful in patients who remain hypotensive despite 
catecholamine and vasopressin therapy. The appropriate dose of parenteral angiotensin II for 
shock is unknown. 
Methods 
In total, 20 patients with distributive shock and a cardiovascular Sequential Organ Failure 
Assessment score of 4 were randomized to either ATII infusion (N = 10) or placebo (N = 10) 
plus standard of care. ATII was started at a dose of 20 ng/kg/min, and titrated for a goal of 
maintaining a mean arterial pressure (MAP) of 65 mmHg. The infusion (either ATII or 
placebo) was continued for 6 hours then titrated off. The primary endpoint was the effect of 
ATII on the standing dose of norepinephrine required to maintain a MAP of 65 mmHg. 
Results 
ATII resulted in marked reduction in norepinephrine dosing in all patients. The mean hour 1 
norepinephrine dose for the placebo cohort was 27.6 ± 29.3 mcg/min versus 7.4 ± 12.4 
mcg/min for the ATII cohort (P = 0.06). The most common adverse event attributable to 
ATII was hypertension, which occurred in 20% of patients receiving ATII. 30-day mortality 
for the ATII cohort and the placebo cohort was similar (50% versus 60%, P = 1.00). 
Conclusion 
Angiotensin II is an effective rescue vasopressor agent in patients with distributive shock 
requiring multiple vasopressors. The initial dose range of ATII that appears to be appropriate 
for patients with distributive shock is 2 to 10 ng/kg/min. 
Trial registration 
Clinicaltrials.gov NCT01393782. Registered 12 July 2011. 
Introduction 
Critically ill patients with shock requiring vasopressors are at a high risk of death. 
Distributive shock is the most common form of shock, and is often caused by sepsis [1]. 
When shock is treated with vasopressors, two main classes of vasopressors are in the 
intensivists’ armamentarium: catecholamines and vasopressin type peptides [1]. Currently, no 
specific type of vasopressor (e.g. norepinephrine, vasopressin, dopamine) compared to 
another vasopressor has been shown to improve outcome [2]. All vasopressors have 
limitations and potential side effects. Patients treated with catecholamines for shock often 
develop tachyphylaxis thereby limiting the utility of these agents, and high doses of 
catecholamines can cause direct cardiotoxicity [3]. The toxic potential of catecholamines has 
been recently demonstrated in a randomized clinical trial of septic shock patients treated 
norepinephrine [4]. In this study, beta-blockade with esmolol was shown to improve survival 
in these patients by decreasing the heart rate. Thus, vasopressors that are not inotropes or 
chronotropes may be useful in patients with shock. One such vasopressor is vasopressin, 
which is most commonly used as an adjuvant with catecholamines. Vasopressin has been 
shown to improve outcomes in patients with less severe septic shock, but has toxicity (i.e. 
cardiac and mesenteric ischemia) at high doses and interacts with hydrocortisone [5]. In the 
subset of critically ill patients in whom mean arterial pressure cannot be maintained with 
vasopressors, distributive shock is uniformly fatal. The addition of a ‘rescue’ vasopressor in 
this setting could be useful. 
Angiotensin II is a naturally occurring hormone with endocrine, autocrine, paracrine, and 
intracrine hormonal effects. It is a potent direct vasoconstrictor, constricting both arteries and 
veins and increasing blood pressure [6].It has a half-life in circulation of approximately 30 
seconds, but while in tissue, its half-life may be as long as 15-30 minutes. Importantly, ATII 
increases secretion of ADH and ACTH, and may potentiate sympathetic effects by direct 
action on postganglionic sympathetic fibers. It also acts on the adrenal cortex, causing it to 
release aldosterone [6,7]. We hypothesized that ATII might serve a role as a useful 
vasopressor in the treatment of shock, but the appropriate dose of intravenous ATII to 
increase blood pressure is unknown. The dose of intravenous ATII previously described has 
varied across studies, but has ranged from 0.4 ng/kg/min to as high as 40 ng/kg/min. The 
highest doses were reported in the cases of profound hypotension due to ACEi overdose 
[8,9]. We set out to determine the appropriate dose of ATII in the treatment of high output 
shock. 
Methods 
The study was conducted at the George Washington University Hospital Intensive Care Unit, 
Washington DC, USA. The trial was registered on clinicatrials.gov (NCT01393782) and the 
study protocol was approved by Food and Drug Administration (IND# BB-IND-11592). The 
protocol was approved by the George Washington University Institutional Review Board. 
Written informed consent was obtained from each participating patient, or appropriate 
surrogate prior to enrollment. The investigators performed all experimental procedures and 
the study coordinators recorded the data. 
Study patients 
Patients were eligible for randomization if they were older than 21 years of age and were 
deemed to have high output shock, which was defined as a cardiovascular Sequential Organ 
Function Assessment (SOFA) score of 4 as well as a cardiac index of > 2.4 liters/min/BSA 
1.73 m
2
 [10]. Patients were also required to have an indwelling arterial line and urinary 
catheter as part of standard care and expected to be present for at least 12 hours during the 
study intervention. In addition, the treating team had to deem the subject adequately volume 
resuscitated and clinically assessed not to be volume responsive (i.e. a fluid bolus would fail 
to increase cardiac index by 15%). Standard of care at our institution is to resuscitate with 20-
30 cc/kg of crystalloid as initial resuscitation. Exclusion criteria included patients with acute 
coronary syndrome, a known history of vasospasm or asthma, any patients currently 
experiencing bronchospasm or patients with active bleeding with an anticipated need for 
transfusion of > 4 units of packed red blood cells, hemoglobin <7 g/dL or any other condition 
that would contraindicate drawing serial blood samples. 
Treatment assignments 
Upon enrollment in the study, patients were randomly assigned following simple 
randomization procedures (computerized random numbers) to receive either angiotensin II 
acetate infusion (Clinalfa, Bachem AG, Hauptstrasse 144, 4416 Bubendorf, Switzerland) or a 
placebo infusion (hereafter referred to as the Study Drug and placebo, respectively). 
Randomization was accomplished by the Investigational Drug Services (IDS) at George 
Washington University Hospital. For the duration of the entire study, only the IDS was aware 
of each patient’s treatment assignment. Unblinding was done after all 20 patients were 
enrolled. All other clinical personnel, including the investigators, clinical support staff, the 
patients and their families were unaware of the treatment assignment for the duration of the 
study. 
Drug infusion 
Enrolled patients were randomized to receive the Study Drug infusion in normal saline 
calculated to run at a drip rate corresponding to an initial concentration of 20 ng/kg/min, plus 
the standard-of-care treatment for high output shock. The Study Drug was prepared in an 
opaque cellophane bag, the contents of which were unknown to the investigators, nurses or 
anyone else taking direct care of the patient. The Study Drug was administered for a total of 6 
hours, with dose (and corresponding drip rate) adjustments made hourly. Study Drug dose 
adjustments were determined per a pre-specified protocol, based on the concomitant 
requirements of standard-of-care therapy (in all cases, norepinephrine infusion plus 
vasopressin, epinephrine and/or phenylephrine infusions) needed to maintain a mean arterial 
pressure (MAP) at or above 65 mm Hg, which is the standard practice at our institution. The 
Study Drug titration protocol was designed to elucidate the dose of ATII that was required (in 
conjunction with a norepinephrine dose between 5-10 mcg/min) to achieve the 
aforementioned standard MAP goal of 65 mm Hg. The dose titration protocol is shown on 
Figure 1. The maximum allowable dose for the ATII titration was 40 ng/kg/min, and the 
minimum was 5 ng/kg/min. At the end of 6 hours, the Study Drug infusion was titrated off by 
being halved every 10 minutes until the Study Drug infusion dose was below 5 ng/kg/min, 
after which it was discontinued. 
Figure 1 Study Drug titration protocol. 
End points 
The primary endpoint was the effect of the ATII infusion on the standing dose of 
norepinephrine which was required to maintain a MAP of 65 mmHg. The secondary 
endpoints included the effect of the ATII infusion on urine output, serum lactate, cardiac 
output, and 30 day mortality. 
Statistical analysis 
This was a safety and dose finding feasibility study. We analyzed a small cohort of patients, 
consistent with similar studies of this nature. We estimated that a population of 20 patients, 
ten patients in each arm, would generate a basis for determining if there was sufficient signal 
for ATII to affect the dose of norepinephrine at the doses outlined herein. An independent 
data and safety monitor (DSM) was assigned and reviewed all adverse events. The DSM had 
the power to be unblinded and halt the study at any time during the conduct of the study. 
We assessed the distribution of demographic and clinical variables. Difference between 
proportions of patients with certain variables was assessed with the chi-square, Fisher exact 
test, student t, and Mann-Whitney test as appropriate. The primary endpoint of the effect of 
the Study Drug infusion on the standing dose of norepinephrine was calculated using a 
general estimating equation analysis and is presented as the mean dose of norepinephrine 
(mcg/min) and Study Drug infusion (in ng/kg/min) at hourly intervals. 
Generalized estimating equation was used to model the response to the Study Drug over time, 
with standard-of-care vasopressor hourly readings beginning at 1 hour prior to, through 8 
hours after the initiation of the Study Drug, using the SAS Genmod procedure (version 9.3, 
Cary, NC). Correlation structure was defined as auto-regressive to account for the likely 
higher correlation between time points that were closer together. In this model, the main 
effect of drug examines the mean response to each drug averaged across times. The main 
effect of time examines the mean response at each time point averaged across drugs, and the 
drug multiplied by time interaction examines whether the change over time differs between 
drugs. 
All values are reported as mean ± standard deviation unless otherwise specified. All other 
statistical analysis was completed using SPSS 18, Chicago, IL, USA. 
Results 
The flow of patients into the study is reported in Figure 2. Twenty patients underwent 
randomization and all 20 patients were enrolled in and completed the study (Figure 1). 
Baseline characteristics of the two groups are shown in Table 1. The mean age for all study 
subjects was 62.9 ± 15.8 years. Of the patients, 75% were male, 45% were Caucasian and 
40% were African American. Baseline SOFA and APACHE II scores were 15.9 ± 3.0 and 
30.6 ± 8.9, respectively. 19 of 20 patients were receiving concomitant vasopressin at a dose 
of 0.02-0.08 u/min. Vasopressin doses were not adjusted during the study period. 
Figure 2 Patient Flow Diagram. 
Table 1 Baseline demographic and clinical data 
 FullCohort SD ATII SD Placebo SD P value
Ϯ
 
Age 62.85 15.81 68.40 17.46 57.30 12.44 0.12 
Male (n) 15  6  9  0.30 
Race (n)        
Caucasian 9  6  3  0.37 
Black 8  3  5  0.65 
Other 3  1  2  1.00 
Severity of Illness        
Baseline SOFA 15.90 2.97 14.9 2.81 16.90 2.92 0.14 
APACHE 30.60 8.86 27.2 9.67 34.00 6.83 0.09 
Past Medical History        
IHD 2  1  1  1.00 
CHF 2  2  0  0.47 
COPD 2  2  0  0.47 
DM 7  4  3  1.00 
CKD 7  3  4  1.00 
HD 1  0  1  1.00 
Liver disease 9  5  4  1.00 
Cancer 6  1  5  0.14 
IS 6  1  5  0.14 
Steroids 3  1  2  1.00 
Hypertension 9  4  5  1.00 
CVA 5  4  1  0.30 
AKI 17  9  8  1.00 
Labs        
WBC 17.38  19.0 16.0 15.72 12.3 0.61 
Hgb 9.45  9.16 2.14 9.73 2.45 0.59 
Creatinine 2.33  1.89 1.03 2.76 1.34 0.12 
pH 7.33  7.34 0.11 7.32 0.12 0.63 
Lactate 5.83  4.59 3.11 7.06 5.16 0.21 
Baseline vasopressor doses
Y
        
Norepinephrine 25.05 17.03 19.80 11.67 30.30 20.37 0.18 
Vasopressin 0.04 0.02 0.03 0.02 0.05 0.02 0.10 
Ϯ
 P values for continuous variables calculated using Student's T test. P values for discrete 
variables calculated using Fisher exact test. 
Y
 One patient in the placebo group received phenylephrine infusion prior to initiation of ATII 
versus no patients in the ATII group. One patient in the placebo group received epinephrine 
versus no patients in the ATII group. 
IHD = ischemic heart disease. CHF = congestive heart failure. COPD = chronic obstructive 
pulmonary disease. DM = diabetes mellitus. CKD = chronic kidney disease. HD = 
hemodialysis. IS = immunocompromised state. CVA = cerebrovascular accident. AKI = 
acute kidney injury. 
ATII resulted in a reduction in norepinephrine dosing in all patients (Figure 3). The mean 
Hour 1 norepinephrine dose for the placebo cohort was 27.6 ± 29.3 mcg/min v. 7.4 ± 12.4 
mcg/min for the ATII cohort (p = 0.06). Hour 2 norepinephrine dosing for the placebo cohort 
was 28.6 ± 30.2 mcg/min v. 7.3 ± 11.9 mcg/min in the ATII cohort (p =0.06). Throughout the 
study period, the mean ATII dose was reduced from 20 ng/kg/min at Hour Zero to 5 
ng/kg/min at Hour 6 before being titrated off by Hour 7 (one hour post-infusion). Despite this 
down-titration of ATII, norepinephrine doses remained substantially lower in the ATII cohort 
than the placebo cohort, though the effect approached statistical significance only at Hours 1 
and 2. Upon cessation of the ATII infusion, mean norepinephrine rebounded concomitantly. 
Figure 3 Changes in Norepinephrine Dose with Concurrent Angiotensin II. 
Using a general estimating equation model with time defined as a continuous variable, in 
order to obtain a global test of interaction effect, the main effect of treatment (Study Drug vs. 
placebo) was not significant (p = 0.13), nor was the effect of time (p = 0.30), nor was the 
treatment multiplied by time interaction (p = .76). When time was defined as a class variable 
with Hour -1 defined as the reference group, in order to examine specific time points, the 
drug effect (p = .14) and time effect (p = .18 at time 0, p = .51 at time 1) both remained non-
significant. The product of drug multiplied by time interaction showed a trend level of 
significance at 1-hr and 2-hr (p = 0.06). 
Adverse events most commonly experienced by all patients were metabolic disorders with 
alkalosis occurring in four patients in the ATII group and zero in the placebo group (p = 
0.09). The most common adverse event thought to be attributable to ATII was hypertension, 
which occurred in 20% of patients receiving ATII (p = 0.58). In both of these patients, the 
Study Drug infusion was stopped, per protocol, in order to achieve MAP goals. Table 2 lists 
adverse events. 
Table 2 Adverse events 
Organ System Total ATII Placebo P value 
Metabolic disorders 16 11 5  
Acidosis  2 3 1.00 
Alkalosis  4 0 0.09 
Blood or lymphatic disorders 7 3 4  
Respiratory disorders 6 3 3  
Worsening respiratory failure  1 3 0.58 
Wheezing  1 0 1.00 
Cardiac disorders 12 7 5  
Hypertension
◊
  2 0 0.58 
Hypotension  2 1 1.00 
Atrial Fibrillation  2 0 0.47 
Renal disorders
Y
 7 6 1  
Decreased urine output  3 1 0.58 
Worsening AKI  0 2 0.47 
Other disorders
Ϯ
 8 5 3  
Worsening MOSF  2 3 1.00 
◊
 ATII infusion was discontinued in two patients due to hypertension. 
Y
 Seventeen of 20 patients exhibited pre-existing AKI, including 8 patients receiving placebo 
and 9 patients receiving ATII. Of the three patients that did not have pre-existing AKI, one 
patient developed AKI and received ATII. 
Ϯ
 Includes worsening multiple organ system failure, fever, lower extremity edema, and thigh 
hematoma. 
AKI = acute kidney injury. MOSF = multiple organ system failure. P values calculated using 
Fisher Exact test. 
Urine output, cardiac output, central venous pressure, and mean arterial pressure are shown in 
Table 3. The 30 day mortality for the two groups were similar for the ATII cohort and the 
placebo cohort (50% v. 60%, p = 1.00). 
  
Table 3 Secondary outcomes 
 Hr -2 Hr -1 Hr 0 Hr 1 Hr 2 Hr 3 Hr 4 Hr 5 Hr 6 Hr 7 Hr 8 
Urine Output           
ATII 41.7(51.7) 28.6(32.4) 45.9(96.5) 31.1(58.0) 33.7(67.1) 42.6(59.8) 35.9(50.0) 34.4(57.2) 36.1(38.3) 27.2(33.3) 23.8(27.3) 
Placebo 29.5(69.8) 12.4(23.2) 23.5(41.8) 17.5(25.7) 17.0(32.0) 16.3(24.6) 17.0(34.7) 16.8(30.4) 14.8(26.3) 18.0(27.3) 23.0(34.4) 
Cardiac Output           
ATII 7.0(2.7) 6.0(3.1) 6.6(2.6) 6.3(2.5) 6.2(2.5) 5.9(2.7) 6.5(2.4) 6.1(2.6) 6.7(3.3) 6.3(2.9) 7.5(3.1) 
Placebo 6.3(1.2) 6.9(2.5) 6.5(1.7) 6.9(1.8) 6.4(1.7) 6.8(3.0) 7.3(2.2) 6.8(1.5) 7.3(1.8) 6.9(2.5) 7.0(2.3) 
CVP           
ATII 12.7(5.5) 12.9(7.0) 14.1(8.9) 14.8(7.3) 14.6(7.4) 14.8(8.8) 11.7(3.9) 12.1(4.8) 10.0(2.9) 12.6(4.8) 11.8(3.8) 
Placebo 16.0 (3.0) 9.7(2.1) 12.6(7.8) 15.7(9.3) 17.3(9.0) 15.7(7.3) 16.4(8.6) 16.3(6.7) 14.2(6.5) 14.4(7.1) 13.2(5.6) 
MAP           
ATII 71.2(13.6) 72.3(11.2) 68.8(7.0) 74.8(8.4) 69.8(8.6) 73.1(12.5) 75.3(14.2) 68.9(8.1) 73.0(10.5) 72.3(11.9) 73.6(11.5) 
Placebo 71.2(9.2) 71.8(6.5) 73.0(12.6) 72.8(9.5) 67.8(6.6) 70.1(6.4) 71.3(7.8) 73.0(4.7) 75.9(9.4) 74.0(10.6) 74.5(13.2) 
Lactate           
ATII   4.6(3.1)      5.2(4.1)   
Placebo   7.1(5.2)      5.7(3.9)   
Legend: Urine Output (cc), Cardiac Output (liters/min), CVP = central venous pressure; all 
variables-mean (s.d.), denotes p < 0.05. 
Discussion 
We report the findings of the first prospective randomized placebo-controlled trial of 
angiotensin II in the treatment of high output shock. Our efforts were intended as a proof-of-
concept and dose finding study, as well as an attempt to generate hypotheses in advance of 
larger future studies. To this end, we have shown that ATII can be an effective pressor agent 
at a dose range of 1-40 ng/kg/min. More specifically, we believe that a starting dose of 2-10 
ng/kg/min may be an appropriate starting dose in the treatment of high output shock when 
used in conjunction with standard-of-care vasopressors. 
Angiotensin II has been used previously in for the treatment of hypotension in a handful of 
cases. Newby et al describe the successful treatment of a patient with an ACE inhibitor 
overdose and profound shock using an ATII infusion [11]. Multiple case reports have shown 
potential utility for ATII in the treatment of septic shock with catecholamine infusions [12-
16]. 
While all patients in the present study had a response to the ATII infusion, we observed 
significant heterogeneity. Of the ten patients who received ATII, two had a modest response, 
while two were exquisitely sensitive to ATII, which was an unexpected finding. In the two 
highly sensitive patients, the norepinephrine infusion was titrated off per protocol, and the 
ATII dose was at its lowest allowable dose of 5 ng/kg/min and the patients remained 
hypertensive with MAP of > 90 mm Hg despite norepinephrine titrated off. Since 
hypertension is not part of our standard of care, the investigators halted the infusion, and the 
ATII was weaned off. In both cases the need for norepinephrine was rapidly reestablished. 
Pre-clinical studies demonstrate that animals that become septic after pre-treatment with 
enalapril are resistant to norepinephrine as a vasopressor [17]. Based on these findings, we 
hypothesized that the two patients who were very sensitive to ATII may have been receiving 
an angiotensin converting enzyme inhibitor prior to developing septic shock, thus explaining 
the exquisite sensitivity of to ATII infusion. However, a detailed chart review revealed 
incomplete information, and we were unable to document pre-morbid angiotensin converting 
enzyme inhibitor exposure. Therefore, the ATII sensitivity that we observed could be due to 
other mechanisms that have not been elucidated. 
We observed that ATII may have synergy with other vasopressors (i.e. catecholamines and 
vasopressin), but may also have another important indication in critically ill patients. 
Previous work in pre-clinical studies suggests that septic animals suffer acute kidney injury in 
part due to intra-glomerular hypotension induced by efferent arteriole vasodilation. In these 
models, intravenous infusion with ATII restored creatinine clearance and urine output [18]. 
While the present study was underpowered to elucidate any effect on urine output, we expect 
further large scale studies will clarify ATII’s effect on kidney function in high output shock. 
In addition, ATII is a potent vasopressor without inotropic or chronotropic properties [19]. 
Recent randomized controlled trials in patients with septic shock treated with norepinephrine 
suggest that less chronotropy may be desirable and may lead to a survival benefit [4]. Based 
on these findings, for patients who require norepinephrine and are tachycardic, ATII may be 
particularly useful. We hypothesize that for patients with severe hypotension, lower doses of 
multiple vasopressors with differing mechanisms of action may be more efficacious and less 
toxic than high doses of one type of vasopressors (i.e. catecholamines). 
The study had multiple strengths. First, the study was a randomized double-blind controlled 
trial with an appropriate placebo control arm. Secondly, it was of pragmatic design, as it was 
the intent of the investigators to enroll patients receiving standard-of-care treatment for high 
output shock. As such, all patients had received a priori appropriate monitoring and 
therapeutic interventions (including central venous lines, bladder catheters, arterial lines, and 
cardiac output monitoring devices). There was no additional need for any specialized 
equipment of procedures prior to enrollment in the study. Thirdly, all enrolled patients had a 
documented need for high dose vasopressor therapy despite volume therapy, as evidenced by 
the cardiac index entry criteria. This, we believe, is in keeping with the current practice of 
addressing volume responsiveness in a hypotensive patient prior to initiation of vasopressor 
therapy. Finally, as part of our study protocol, we employed the use of a data safety monitor, 
who had the ability to unblind data and evaluate for adverse events as well as halt the study, 
neither of which occurred. 
The study had several limitations. First, the study had a modest sample size. As such, we 
were unable to make conclusions regarding the effect of ATII on urine output due to the high 
incidence of oliguria and renal replacement therapy in both the ATII group and the placebo 
group. Moreover, this study was not powered adequately to discern a difference in mortality 
between the ATII and placebo groups. Second, there were some imbalances between our 
placebo arm and our drug arm, the former of which were younger, but sicker (according to 
both SOFA and APACHE II scores). It is possible that differences in these two populations 
influenced the effectiveness of ATII. Finally, inclusion criteria for enrollment in the study 
were such that the resulting study population was critically ill, with an expected mortality in 
excess of 50%. Indeed, our requirement of cardiovascular SOFA score of 4 (indicating a 
norepinephrine dose of 0.1mcg/kg/min) would, on average, equate to a minimum 
norepinephrine dose of 9.3mcg/min, which based on our Study Drug titration protocol 
(Figure 1), would leave little room for titration. In order to allow for the possibility of a 
meaningful signal upon initiation of ATII, we preferentially considered patients with a 
substantially higher starting dose of norepinephrine (20-30 mcg/min, as evidenced in Figure 
3). Moreover, we preferentially considered patients with an upward-trending norepinephrine 
requirement, signifying refractoriness to therapy. Based on these facts, our results may not be 
generalizable to a less sick population. However, we foresee a use for ATII in a significant 
critically ill population, for whom multiple vasopressors are required. 
Conclusions 
In conclusion, the initiation of an ATII infusion in patients receiving norepinephrine for 
septic shock resulted in a marked decrease in norepinephrine doses. ATII may be effective as 
a novel pressor agent in the treatment of high output shock. Initial dosing ranges are most 
likely between 2-10 ng/kg/min. In our pilot study, the drug appears to be well-tolerated. 
Further randomized placebo-controlled trials to more fully elucidate ATII’s role as a 
vasopressor in the treatment of shock are warranted. 
Key messages 
• Angiotensin II improved blood pressure in patients with high-output shock and multiple 
vasopressors. Angiotensin II may have a role as a rescue vasopressor. 
• The response to angiotensin II in a modest sized study were highly variable 
• The precise role of angiotensin II in the treatment of hypotension and shock needs further 
study 
• Angiotensin II was well-tolerated in this pilot study 
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